Organization & Developments: AstraZeneca

Parents

AstraZeneca PLC (NASDAQ:AZN)*

Children

*AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
*AstraZeneca Pharmaceuticals (Ireland) Ltd
*For years, British drug maker AstraZeneca PLC concentrated on developing small-molecule drugs made from chemical compounds.
*Under CEO David Brennan, the pharmaceuticals giant is making a big bet on "large molecule" drugs, also widely known as biologicals
2010: Targacept Receives $200 Million Upfront Payment from AstraZeneca (2010)
2013: AstraZeneca Pharmaceuticals Corporate Giving Program (2013)
2014: AstraZeneca board rejects Pfizer takeover offer
2014: AstraZeneca struck deals with UK's Immunocore for Cancer Drug (2014)
2014: Horizon Discovery bags second AstraZeneca contract (2014)
2014: How can Pfizer acquire AstraZeneca and streamline business?
2015: 100,000 Genomes Project taps Big Pharma dream team for data crunching skills
2015: AstraZeneca struggles to spin out anti-infectives division, coming down to the wire
2016: Biotech Daily Digest: Array In Spotlight; Pain Continues; Medivation Contest Heats Up - Array BioPharma Inc. (NASDAQ:ARRY)
2016: Dynavax Technologies: An Updated View After FDA Decision - Dynavax Technologies Corporation (NASDAQ:DVAX)
2018: AstraZeneca's Late-Stage Study Win Reinforces Its Hold On Particular Segment Of Lung Cancer Market - AstraZeneca Group plc (NYSE:AZN)
2020: ASCO: AstraZeneca's Tagrisso, headed for big sales boost, cuts lung cancer recurrence by 83%
2020: AstraZeneca vaults ahead in COVID-19 vaccine race with 'landmark' Oxford deal
2020: AstraZeneca, Oxford herald 70% average efficacy for Covid-19 vaccine, touting easier distribution, lower price
2020: AstraZeneca, U. of Oxford Report Positive Phase I/II Data for COVID-19 Vaccine Candidate
2020: BARDA hands AstraZeneca $1B-plus to race through PhIII and ramp up fall deliveries of Oxford’s pandemic vaccine – Endpoints News
2020: Report: AstraZeneca's COVID-19 Vaccine Generates Antibodies and T-Cells Against the Virus in Phase I Trial
2021: Mila announces collaboration with AstraZeneca to maximize the potential of AI for drug discovery and development
2021: Startup Behind AstraZeneca Covid-19 Vaccine Raises $168 Million in Step Toward IPO
2022: AstraZeneca ADC barrels forward as Keytruda combo data make case for lung cancer use
2022: AstraZeneca PLC 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: AstraZeneca: Acquisitions And Some Thoughts About Biotech Investing_ seekingalpha.com
2022: AstraZeneca: Most Promising Pharmaceutical Company During A Recession_ seekingalpha.com
2022: AstraZeneca: Q322 Earnings Boost Share Price, Narrowing The Long-Term Upside Opportunity _ seekingalpha.com
2022: Illumina joins with AstraZeneca on AI-driven drug discovery project
2023: AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test
2023: AstraZeneca launches Evinova to bring AI to clinical trials
2023: AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition_seekingalpha.com
2023: AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity
2023: AstraZeneca: Late-Stage Pipeline Looks Increasingly Well Positioned to Support Long-Term Growth
2023: Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?_ seekingalpha.com
2023: Lung cancer deaths cut in half with AstraZeneca pill, large trial finds_nbcnews
2023: New effort aims to build an African ancestry biobank_ axios
2023: Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win_ seekingalpha.com
2024: 5 Reasons AstraZeneca Stock Can Rise In 2024
2024: ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting
2024: AstraZeneca PLC 2023 Q4 - Results - Earnings Call Presentation
2024: AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
2024: AstraZeneca: Strong In A Weak Market
2024: AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth
2024: AstraZeneca's vision for the future of respiratory care
2024: Drugging The Undruggable Strategies And Future Directions
2024: What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals
2024: With new Enhertu data, an ADC could overtake chemo in breast cancer
2024:AZ's Truqap delivers phase 3 win in prostate cancer subtype after recent breast cancer miss
2025: AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology
2025: AstraZeneca antibody protects macaques from severe bird flu, suggesting prophylactic potential in case of outbreak
2025: AstraZeneca Opens $300 Million Cell Therapy Manufacturing Facility in Montgomery County
2025: AstraZeneca outlines $3.2 dividend hike and anticipates strong 2025 growth
2025: AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold
2025: AstraZeneca quietly exits neuroscience
2025: AstraZeneca: A Big Pharma Blue Chip To Buy Now_ seekingalpha.com
2025: AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector
2025: AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet
2025: AstraZeneca: Just What The Doctor Ordered
2025: AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating_ seekingalpha.com
2025: AstraZeneca’s SWOT analysis: pipeline strength fuels stock potential
2025: Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
2026: #8 Baxdrostat, Company: AstraZeneca Used for: Hypertension Est. 2032 sales: $2 billion
2026: #9 Camizestrant, Company: AstraZeneca Used for: HR-positive breast cancer Est. 2032 sales: $2 billion
AstraZeneca Health Innovation Ventures

Jumps

*Key People: AstraZeneca
Finance & Acquisition: AstraZeneca

Made with TheBrain